Tags : Immunotherapies

Eisai Signs a Research and Option Agreement with Numab to

Shots: Numab to receive up front, research funding, success fees, milestones & royalties on sales. Eisai to get an option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules developed utilizing Numab’s MATCH platform The focus of the agreement is to leverage Numab’s multi-specific technology to generate cancer therapies providing superior […]Read More

Thyas Signs an Exclusive License Agreement with iPS Academia Japan

Shots: iPS Academia Japan to receive payments from Thyas. Thyas to get exclusive patent rights for production and usage of iPS cell-derived T cells, with non-exclusive rights for its development and commercialization The focus of the agreement is to develop tumor-specific or virus-specific T cells using iPS’ technology, with proliferative capacity and potent killing capability […]Read More

Eli Lilly Collaborates with Aduro Biotech for its cGAS-STING Pathway

Shots: Aduro to receive $12M upfront, up to $620M milestones and royalties on sales from Lilly. Lilly to get rights for Aduro’s cGAS-STING pathway inhibitor program and will be responsible for all costs for its global commercialization Lilly to fund the research program, Aduro will be responsible for the research of molecules in cGAS-STING Pathway Inhibitor Program with an option […]Read More

Leidos Collaborates with GeoVax for the Development of Immunotherapies for

Shots: The companies will jointly develop vaccine candidates using Leidos’ PD-1 checkpoint inhibitors combined with GeoVax’s MVA-VLP vaccine platform GeoVax will design, construct, and characterize the developed product and further analysis will be done by Leidos GeoVax’s Modified Vaccinia Ankara (MVA) platform is used for developing in-vivo vaccines in the form of multimeric proteins or […]Read More

Merck Partnered with Dragonfly for Development and Commercialization of Immunotherapies

Shots: Dragonfly Therapeutics will receive an upfront $695M with milestone and royalties on sales and Merck to get option to license exclusive worldwide IPR rights of products developed using Dragonfly’s TriNKET technology The agreement is focus on developing and providing immunotherapies using TriNKET technology platform to treat solid malignancies TriNKET technology is based on NK […]Read More